WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H465244
CAS#: unknown
Description: BADP is a is a cationic lipid for RNA and vaccine delivery.
Hodoodo Cat#: H465244
Name: BADP
CAS#: unknown
Chemical Formula: C39H78N2O4S4
Exact Mass: 766.48
Molecular Weight: 767.303
Elemental Analysis: C, 61.05; H, 10.25; N, 3.65; O, 8.34; S, 16.71
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: BADP;
IUPAC/Chemical Name: bis(2-(dodecyldisulfanyl)ethyl) 3,3'-((3-(dimethylamino)propyl)azanediyl)dipropionate
InChi Key: KEEDANUIQHUIOP-UHFFFAOYSA-N
InChi Code: InChI=1S/C39H78N2O4S4/c1-5-7-9-11-13-15-17-19-21-23-34-46-48-36-32-44-38(42)26-30-41(29-25-28-40(3)4)31-27-39(43)45-33-37-49-47-35-24-22-20-18-16-14-12-10-8-6-2/h5-37H2,1-4H3
SMILES Code: CN(C)CCCN(CCC(OCCSSCCCCCCCCCCCC)=O)CCC(OCCSSCCCCCCCCCCCC)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 767.30 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Quentin LL, Nelson CI, Wright CD, Arias MC, Mittinty MM, McNeil DW. Development and validation of the Brief Assessment of Distress about Pain. Eur J Pain. 2021 Jul;25(6):1292-1302. doi: 10.1002/ejp.1751. Epub 2021 Apr 13. PMID: 33619787.
2: Tang Q, Liu J, Jiang Y, Zhang M, Mao L, Wang M. Cell-Selective Messenger RNA Delivery and CRISPR/Cas9 Genome Editing by Modulating the Interface of Phenylboronic Acid-Derived Lipid Nanoparticles and Cellular Surface Sialic Acid. ACS Appl Mater Interfaces. 2019 Dec 18;11(50):46585-46590. doi: 10.1021/acsami.9b17749. Epub 2019 Dec 9. PMID: 31763806.
3: Kertmen A, Przysiecka Ł, Coy E, Popenda Ł, Andruszkiewicz R, Jurga S, Milewski S. Emerging Anticancer Activity of Candidal Glucoseamine-6-Phosphate Synthase Inhibitors upon Nanoparticle-Mediated Delivery. Langmuir. 2019 Apr 16;35(15):5281-5293. doi: 10.1021/acs.langmuir.8b04250. Epub 2019 Apr 3. Erratum in: Langmuir. 2019 Nov 5;35(44):14397. PMID: 30912436.
